Boehringer Ingelheim Posts Sales Growth as Obesity Drug Filing Awaits
Boehringer Ingelheim’s top-selling drug lifted sales in the first half, as the German drugmaker gears up to file for U.S. approval of a new obesity medicine.
The Source
TWSJ
Business
AT&T and Verizon Look Beyond the Family Plan
TWSJ·1h ago·3 min read
Business
U.S. Producer-Price Index Fell in June
TWSJ·1h ago·3 min read
Business
China’s Crude Buying Pause Has Helped Cushion the Market. That Might Be Changing.
TWSJ·1h ago·3 min read
Business
Newark’s Having Trouble Again—And Summer Air Travel Is at Stake
TWSJ·33m ago·3 min read
Related
On this beat
Health
Trump’s Latest Nominee for C.D.C. Director Will Face Senate Panel
TNYT·5h ago·3 min read
Health
‘Sully,’ ‘Miracle on the Hudson’ Pilot, Announces Alzheimer’s Diagnosis
TNYT·16h ago·3 min read
Health
It’s been three months since Lilly launched its obesity pill. Most people are taking Novo’s pill instead.
TWSJ·14h ago·3 min read
Health
CDC looking into several items potentially linked to cyclospora parasite
CBS NEWS·14h ago·3 min read